These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 14983972)

  • 1. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.
    Hegde SS; Mammen M; Jasper JR
    Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Muscarinic receptors in the bladder: from basic research to therapeutics.
    Hegde SS
    Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic receptor antagonists for overactive bladder.
    Abrams P; Andersson KE
    BJU Int; 2007 Nov; 100(5):987-1006. PubMed ID: 17922784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolterodine extended-release for overactive bladder.
    Chung DE; Te AE
    Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solifenacin in the management of the overactive bladder syndrome.
    Robinson D; Cardozo L
    Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Changes in muscarinic receptors of the aging bladder].
    Andersson KE; Schröder A
    Urologe A; 2004 May; 43(5):552-6. PubMed ID: 15098089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
    Hashim H; Abrams P
    Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darifenacin in the treatment of overactive bladder.
    Parsons M; Robinson D; Cardozo L
    Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin.
    Perfetto EM; Subedi P; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S150-7. PubMed ID: 16161388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder.
    Maruyama S; Oki T; Otsuka A; Shinbo H; Ozono S; Kageyama S; Mikami Y; Araki I; Takeda M; Masuyama K; Yamada S
    J Urol; 2006 Jan; 175(1):365-9. PubMed ID: 16406943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacotherapy of overactive bladder.
    Athanasopoulos A
    Expert Opin Pharmacother; 2011 May; 12(7):1003-5. PubMed ID: 21291348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia.
    Kaplan SA; Roehrborn CG; Dmochowski R; Rovner ES; Wang JT; Guan Z
    Urology; 2006 Aug; 68(2):328-32. PubMed ID: 16904446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic receptor subtypes and management of the overactive bladder.
    Chapple CR; Yamanishi T; Chess-Williams R
    Urology; 2002 Nov; 60(5 Suppl 1):82-8; discussion 88-9. PubMed ID: 12493364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
    Kay GG; Abou-Donia MB; Messer WS; Murphy DG; Tsao JW; Ouslander JG
    J Am Geriatr Soc; 2005 Dec; 53(12):2195-201. PubMed ID: 16398909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.